Glycine

Glycine

SCHEMBL343653

NCC(=O)O.N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D

The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 4/20 0.57
PTGS1 P23219 1/20 0.49
GSTK1 Q9Y2Q3 1/20 0.49
DPP4 P27487 1/20 0.49
DPP8 Q6V1X1 1/20 0.49
DPP9 Q86TI2 1/20 0.49
ACE P12821 1/20 0.47
GRM8 O00222 1/20 0.47
GRM6 O15303 1/20 0.47
GRIN2D O15399 1/20 0.47
GRIN3B O60391 1/20 0.47
GSR P00390 1/20 0.47
CYP1A2 P05177 1/20 0.47
GRIK1 P39086 1/20 0.47
GRM5 P41594 1/20 0.47
GRIA1 P42261 1/20 0.47
GRIA2 P42262 1/20 0.47
GRIA3 P42263 1/20 0.47
SLC1A3 P43003 1/20 0.47
SLC1A2 P43004 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL210006 0.95 FOLH1 (0.62) FOLH1PTGS1GSTK1DPP4DPP8
SCHEMBL15420941 0.95 FOLH1 (0.62) FOLH1PTGS1GSTK1DPP4DPP8
SCHEMBL15420942 0.95 FOLH1 (0.62) FOLH1PTGS1GSTK1DPP4DPP8
SCHEMBL210315 0.95 FOLH1 (0.62) FOLH1PTGS1GSTK1DPP4DPP8
SCHEMBL536354 0.95 FOLH1 (0.62) FOLH1PTGS1GSTK1DPP4DPP8
SCHEMBL27611015 0.92 FOLH1 (0.58) FOLH1PTGS1GSTK1DPP4DPP8
SCHEMBL16770243 0.92 FOLH1 (0.58) FOLH1PTGS1GSTK1DPP4DPP8
SCHEMBL27611010 0.92 FOLH1 (0.58) FOLH1PTGS1GSTK1DPP4DPP8
Glycine SCHEMBL2793248 0.91 ALOX15 (0.47) FOLH1PTGS1GSTK1DPP4DPP8
SCHEMBL9760353 0.91 FOLH1 (0.61) FOLH1PTGS1GSTK1DPP4DPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1361860-A4 MODULATED RELEASE PARTICLES FOR AEROSOL DELIVERY KOS LIFE SCIENCES INC (US) 2009-06-03 EP claimed
EP-1361860-A1 MODULATED RELEASE PARTICLES FOR AEROSOL DELIVERY Aeropharm Technology Incorporated (US) 2003-11-19 EP claimed
WO-2002066011-A1 MODULATED RELEASE PARTICLES FOR AEROSOL DELIVERY AEROPHARM TECHNOLOGY, INC. (US) 2002-08-29 WO claimed
WO-2002029416-A2 METHOD FOR DETERMINING CHEMICAL REACTIVITY PHARMACIA & UPJOHN COMPANY (US) 2002-04-11 WO claimed
CN-117915891-A Combination therapy for the treatment of liver diseases 甘莱制药有限公司 2024-04-19 CN disclosed
CN-117915914-A Combination therapy for treating liver diseases 甘莱制药有限公司 2024-04-19 CN disclosed
CN-109884017-A Based on ZGC and MnO2Detection of the fluorescent optical sensor of nanometer sheet to glutathione 济南大学 2019-06-14 CN disclosed
US-20120012123-A1 COMPOSITIONS, ARTICLES AND METHODS FOR PREVENTING OR REDUCING TOBACCO-ASSOCIATED DAMAGE TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2012-01-19 US disclosed
US-20100179133-A1 COMPOSITIONS, ARTICLES AND METHODS COMRISING TSPO LIGANDS FOR PREVENTING OR REDUCING TOBACCO-ASSOCIATED DAMAGE TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2010-07-15 US disclosed
US-20100166833-A1 Compositions, articles and methods for preventing or reducing tobacco-associated damage TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2010-07-01 US disclosed
EP-2170274-A1 COMPOSITIONS, ARTICLES AND METHODS COMPRISING TSPO LIGANDS FOR PREVENTING OR REDUCING TOBACCO-ASSOCIATED DAMAGE Technion Research and Development Foundation, Ltd. (IL) 2010-04-07 EP disclosed
EP-2152102-A2 COMPOSITIONS, ARTICLES AND METHODS FOR PREVENTING OR REDUCING TOBACCO-ASSOCIATED DAMAGE Technion Research & Development Foundation Ltd. (IL) 2010-02-17 EP disclosed
US-7271161-B2 Platinum complexes as antitumor agents in combination with biochemical modulation BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2007-09-18 US disclosed
EP-1536864-A2 PLATINUM COMPLEXES AS ANTITUMOR AGENTS IN COMBINATION WITH BIOCHEMICAL MODULATION BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) 2005-06-08 EP disclosed
US-20040097423-A1 Platinum complexes as antitumor agents in combination with biochemical modulation BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-05-20 US disclosed
WO-2004024062-A2 PLATINUM COMPLEXES AS ANTITUMOR AGENTS IN COMBINATION WITH BIOCHEMICAL MODULATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2004-03-25 WO disclosed
WO-2003000172-A2 METHODS, PHARMACEUTICAL COMPOSITIONS, ORAL COMPOSITIONS, FILTERS AND TOBACCO PRODUCTS FOR PREVENTING OR REDUCING TOBACCO SMOKE-ASSOCIATED INJURY IN THE AERODIGESTIVE TRACT OF A SUBJECT TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2003-01-03 WO disclosed
WO-2002029416-A2 METHOD FOR DETERMINING CHEMICAL REACTIVITY PHARMACIA & UPJOHN COMPANY (US) 2002-04-11 WO disclosed
EP-0674505-A1 SYNERGISTIC COMBINATIONS OF ACTIVE SUBSTANCE FOR THE COSMETIC OR DERMATOLOGICAL CARE OF THE SKIN, HAIR AND NAILS Beiersdorf Aktiengesellschaft (DE) 1995-10-04 EP disclosed
WO-1994014412-A1 SYNERGISTIC COMBINATIONS OF ACTIVE SUBSTANCE FOR THE COSMETIC OR DERMATOLOGICAL CARE OF THE SKIN, HAIR AND NAILS BEIERSDORF AG (DE) 1994-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097423-A1 Platinum complexes as antitumor agents in combination with biochemical modulation TP53, GGT1, APEX1 FOLH1 101/4885PTGS1 305/4885GSTK1 6/4885
US-20100166833-A1 Compositions, articles and methods for preventing or reducing tobacco-associated damage SOD1, SOD3, MGMT FOLH1 148/4885PTGS1 577/4885GSTK1 72/4885
US-20100179133-A1 COMPOSITIONS, ARTICLES AND METHODS COMRISING TSPO LIGANDS FOR PREVENTING OR REDUCING TOBACCO-ASSOCIATED DAMAGE TACR2, TSPO, GABRB3 FOLH1 1597/4885PTGS1 364/4885GSTK1 437/4885
US-20120012123-A1 COMPOSITIONS, ARTICLES AND METHODS FOR PREVENTING OR REDUCING TOBACCO-ASSOCIATED DAMAGE SOD1, SOD3, MGMT FOLH1 148/4885PTGS1 577/4885GSTK1 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.